Stock Taper 
Progyny, Inc. offers fertility and family building benefits, including personalized support, pharmacy services, and surrogacy/adoption reimbursement, to U.S. employers.
A benefits management platform for employers offering employees access to fertility, family building, and women's health services through 'Smart Cycle' coverage, specialist networks, and personalized concierge support.
Progyny reported a 9% year-over-year revenue increase to $311.7 million in its third-quarter 2025 earnings release. Following these strong results and a successful selling season that added approximately 900,000 new covered lives, the company raised its full-year revenue guidance to between $1.263 and $1.278 billion and announced a $200 million share repurchase program, signaling confidence in its financial health and future growth.
Progyny acquired BenefitBump, a parental leave benefits navigation platform, in January 2025. This acquisition marks a significant expansion of Progyny's services beyond its core fertility and family-building offerings to provide continuous support for families from pregnancy through early childhood.
Progyny (PGNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Investors interested in Medical Services stocks are likely familiar with Progyny (PGNY) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
Expecting 1.2 Million New Covered Lives from Commitments to Date and Anticipated Remaining Decisions Reflects How Employers are Increasingly Turning to Solutions with a Proven Track Record of Delivering Savings, Total Cost Management and ROI Progyny's Solutions Creating Compelling Opportunities for Employers to Stem Impacts from Broader Medical Cost Inflation Trend While Maintaining or Expanding Coverage of Services Impactful to their Workforce NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today revealed key insights from the Company's current annual selling season, based on both commitments received to date and anticipated remaining decisions which are expected to contribute 1.2 million new covered lives from launches throughout the first half of 2027. Employers are now weighing how to best meet the complex needs of their workforce while simultaneously wrestling with the broader escalation in the overall medical cost trend.
Overall rating: A-
| PEER | PRICE | |
|---|---|---|
 TXG | $82.85 | COMPARE |
 HQY | $93.23 | COMPARE |
 UFPT | $301.11 | COMPARE |
 SDGR | $28.82 | COMPARE |
 ALVO | $6.08 | COMPARE |
 OMCL | $35.18 | COMPARE |
 OMDA | $20.79 | COMPARE |
 GDRX | $3.28 | COMPARE |
